Mescaline for Chronic Pain

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published: February 18, 2026
Journal: JAMA Psychiatry
Authors: Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.

Paywallindividual

Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes

In a nationally representative sample of 213,437 US adults, lifetime MDMA/ecstasy use was associated with lower odds of lifetime (aOR 0.84), past‑year (aOR 0.84) and past‑year severe (aOR 0.82) major depressive episodes, and psilocybin use was associated with modestly reduced odds of past‑year (aOR 0.90) and past‑year severe (aOR 0.87) MDEs. Other substances were either unrelated or linked to increased MDE odds, and the authors call for experimental studies to test causality and therapeutic potential.

Published: January 5, 2022
Journal: Journal of Psychopharmacology
Authors: Jones, G. M., Nock, M. K.

Open Accessindividual

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin

This double-blind, placebo-controlled, cross-over study (n=10) finds that a medium dose of psilocybin (10mg/70kg) significantly reduced migraines (headaches) in the two weeks after dosing.

Published: January 1, 2021
Journal: Neurotherapeutics
Authors: Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H., Luddy, C., Flynn, L. T., Lindsey, H., Pittman, B. P., Cozzi, N. V., D’Souza, D. C.

Open Accessmeta

Psychedelics

This paper is the most comprehensive review of psychedelics research up to 2016 by the eminent David E. Nichols.

Published: April 1, 2016
Journal: Pharmacological Reviews
Authors: Nichols, D. E.

Company

Product

Legal

Mescaline

Chronic Pain

Academic Research

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin

Psychedelics

Clinical Trials

Explore further